Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Zelira Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $5.95 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 11.90 million
Earnings per share -0.316
Dividend per share N/A
Year To Date Return 17.65%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

Zelira Therapeutics Ltd (ASX: ZLD)
Latest News

a woman
⏸️ Investing

Why these 4 ASX shares have started the week deep in the red

The Domino's Pizza Enterprises Ltd. (ASX:DMP) share price is one of four starting the week deep in the red. Here’s…

Read more »

a woman
⏸️ Investing

Aussie pot stock update: Here's what you missed this month

The Auscann Group Holdings Ltd (ASX:AC8) share price is one of a number in the pot stock industry to have…

Read more »

a woman
⏸️ Investing

Pot stocks are not winning any brownie points

The pot stocks aren’t doing a great job of growing your capital.

Read more »

a woman
⏸️ Investing

Pot stocks start the week strongly: Here's what you need to know

The Auscann Group Holdings Ltd (ASX:AC8) share price is one of a number in the medicinal cannabis industry which have…

Read more »

a woman
⏸️ Investing

Put your life savings in pot stocks – but first, read this

Three crucial things will make or break the likes of Auscann Group Holdings Ltd (ASX:AC8) and MMJ Phytotech Ltd (ASX:MMJ).

Read more »

a woman
⏸️ Investing

Aussie pot stocks storm higher: Here's what you need to know

The Cann Group Limited (ASX:CAN) share price and the Hydroponics Company Ltd (ASX:THC) share price have been big movers today.…

Read more »

a woman
⏸️ Investing

Why these 4 ASX shares have rocketed higher today

The iSentia Group Ltd (ASX:ISD) share price has been one of four climbing higher today. Here’s why…

Read more »

a woman
⏸️ Investing

Pot stocks CRUSHED: Here's what you need to know

The Auscann Group Holdings Ltd (ASX:AC8) share price is down and a number of other pot stocks are being crushed…

Read more »

a woman
⏸️ Investing

S&P/ASX 200 finishes higher Monday: 8 shares you missed

The S&P/ASX 200 (Index:^AXJO)(ASX:XJO) ended higher on Monday with share price gains from Vocus Group Ltd (ASX:VOC) and Aconex Ltd…

Read more »

a woman
⏸️ Investing

Here's why these 4 ASX shares have started the week with a BANG

The Aconex Ltd (ASX:ACX) share price is one of four shooting higher today. Here’s why they have started the week…

Read more »

a woman
⏸️ Investing

Why these 4 shares are getting slammed on Friday

Shares like Vocus Group Ltd (ASX: VOC) are not enjoying a good end to the week.

Read more »

a woman
⏸️ Investing

These 3 ASX shares just raced to 52-week highs: Can they keep going?

The Zelda Therapeutics Ltd (ASX:ZLD) share price is one of three that have just hit 52-week highs. Can they keep…

Read more »

ZLD ASX Announcements

An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
YesNo

About Zelira Therapeutics Ltd

Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema, and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer. The company is organised into two operating segments based on geographic location of operations: Australia and United States of America.

Director Transactions Data provided by Morningstar.

Data provided by Morningstar.
Date Director Type Amount Value Notes
04 Dec 2025 Oludare Odumosu Issued 386,847 $100,000
As advised by the company. USD, convertible notes Issue
04 Dec 2025 Donna O'Donnell Issued 193,423 $50,000
As advised by the company. USD 50,000, 193,423 Convertible Notes Issue

Directors & Management Data provided by Morningstar.

Data provided by Morningstar.
Name Title Start Date Profile
Mr Timothy (Tim) Ryan Slate Company SecretaryNon-Executive Director Dec 2016
Mr Slate provides accounting and secretarial advice to private and public companies. He has over 15 years' experience in chartered accounting.
Dr Oludare Odumosu Managing Director Dec 2019
Mr Osagie Imasogie has over 30 years of experience in law, finance, business management, healthcare, and the pharmaceutical industry. He is co-founder and Senior Managing Partner of PIPV Capital, a Private Equity firm focused on the Life Sciences sector. Prior to co-founding PIPV Capital, he conceptualized and established GlaxoSmithKline Ventures and was its founding Vice President. He has held senior legal, commercial, and R&D positions at pharmaceutical companies including GSK, SmithKline, DuPont Merck, and Endo, where he was founding General Counsel and Senior Vice President for Corporate Development.
Mr Osagie Imasogie Non-Executive ChairmanNon-Executive Director Dec 2019
Dr Odumosu was Ilera Healthcare's first Chief Operating Officer, leading the design, implementation, and management of Ilera's business operations following its license award in 2017. He oversaw day-to-day operations of Ilera's vertically integrated grower/processor, wholesale, and dispensary and led the formulation of Ilera's proprietary cannabinoid-based product.
Mr Greg Blake Executive Director Feb 2023
Mr Blake has led the strategic development and commercialisation of several products across various therapeutic categories. He has nearly 20 years of experience in healthcare, building a foundation of knowledge across marketing and the commercial value chain. His work with Rhythm Biosciences as General Manager led the company through the establishment of the pre-launch critical pathway and commercialisation planning for both domestic and international markets.
Dr Donna Gentile O'Donnell Non-Executive Director Jun 2023
Dr O'Donnell has led a diverse career in healthcare, life sciences, and public service focused in the Greater Philadelphia area. She was formerly a principal with O'Donnell Associates, working with clients including non-profit organisations, universities, and life science companies such as Cephalon Pharmaceuticals.

Top Shareholders Data provided by Morningstar.

Data provided by Morningstar.
Name Shares Capital
Mr Malik Majeed 1,134,644 9.54%
Sunset Capital Management Pty Ltd 573,725 4.82%
Securities Vault Pty Ltd 488,059 4.10%
Quincy Street Capital Llc 456,622 3.84%
Sharri J Rochlin 393,168 3.30%
Osagie Imasogie 393,168 3.30%
Mr Zoltan Kerekes 393,168 3.30%
Ms Lisa Gray 381,988 3.21%
BNP Paribas Nominees Pty Ltd 341,932 2.87%
Mera I Llc\C 332,479 2.79%
Mr Torsten M Geers 307,454 2.58%
Mr Steve Shapiro 302,571 2.54%
Mara Gordon 252,242 2.12%
Mr Saul Shorr Mrs Margaret Shorr 151,285 1.27%
Dr Chanda Latrice Macias 146,479 1.23%
Mera Ii Llc\C (i) 133,372 1.12%
Oludare Odumosu 131,766 1.11%
Citicorp Nominees Pty Limited 121,342 1.02%
Mr Daniel Hexter Mrs Shannon Hexter 103,389 0.87%
Geers Egag Llc 85,715 0.72%

Profile

since

Note